According to the findings of a study published in "The International Journal of Molecular Sciences" medicinal cannabis has positive applications in painful menstruation treatment. Up to 90% of females of reproductive age experience dysmenorrhea, and medical therapies include over-the-counter analgesics or hormonal contraception. Cannabis's medical uses and analgesic abilities have recently attracted a lot of attention. This study sought to critically examine recent studies on the use of cannabis as a painkiller and explore its use for dysmenorrhea treatment.

Cochrane Library (Wiley), PubMed, EMBASE, MEDLINE, clinicaltrials.gov, and Google Scholar were searched using relevant terms, such as medicinal cannabis, cannabinoids, tetrahydrocannabinol, dysmenorrhea, clinical trial, and pain. A total of 84 publications were screened in order to find the pertinent studies, and 20 of them were deemed unnecessary. For pain management, the mechanism and qualities of cannabis-based therapies were explored.

Additionally, it summarized all scientific studies done on cannabis as a painkiller. Adverse effects were also highlighted. Barriers to use as well as the safety and toxicity of medicinal cannabis were elucidated. The clinical studies' two-thirds summarized corroborated positive analgesic results, with the three most common adverse effects being dry mouth, nausea, and sleepiness.

The use of medical cannabis to relieve dysmenorrhea exhibits promising outcomes. In 2021, the global medical cannabis market size was estimated at USD 11.0 billion. From 2022 to 2030, it is expected to elevate at a CAGR of 21.06%. This would promote research on the use of medical cannabis in unmet clinical diseases from academic institutions as well as the pharmaceutical and medical device industries.